300x60 Goldinvest Banner

Cannabis

  • Wichtige Fortschritte in Kolumbien: Die Cannabisgesellschaft Chemesis International (CSE CSI / FRA CWAA) wartet heute Morgen mit äußerst positiven Nachrichten von ihrer 100%igen Tochtergesellschaft La Finca Interacviva-Arachna Med auf. Wie man nämlich mitteilte, hat La Finca vom kolumbianischen Justizministerium die Genehmigung für drei neue Anbaulizenzen erhalten!

  • Vergangene Woche stimmte der kalifornische Senat für ein Gesetz, das die Schaffung von vom Bundesstaat genehmigten Banken ermöglicht, die im Marihuanamarkt aktiv werden könnten.

  • Kalifornien veröffentlichte vor Kurzem die Zahlen zu den Verbrauchssteuern des ersten Quartals 2019. Daraus lässt sich Medienberichten zufolge schließen, dass der Umsatz mit Cannabis als Genussmittel im Vergleich zum Vorjahreszeitraum um 92% von 231 auf 490,3 Mio. USD stieg.

  • Canopy Growth (WKN A140QA), die größte Cannabisgesellschaft der Welt, hat die britische Kosmetikmarke This Works übernommen und sich diesen Deal 43 Mio. Pfund kosten lassen. Der kanadische Konzern will nun eine Produktreihe herausbringen, die den Wirkstoff Cannabidiol (CBD) enthält. Dabei geht es um Produkte, die einen gesünderen Schlaf und eine bessere Hautpflege unterstützen sollen.

  • Bankenvereinigung aller 50 US-Bundesstaten und eines US-Territoriums rufen den Bankenausschuss des Senats auf, die überparteiliche Gesetzgebung voranzubringen, die Finanzinstitute vor der Verfolgung durch die Bundesbehörden schützen soll, welche mit der Marihuanaindustrie zusammenarbeiten.

  • Vancouver, British Columbia / 22. Mai 2019 – AgraFlora Organics International Inc.(„AgraFlora“ oder das „Unternehmen“) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: PUFXF), ein wachstumsorientiertes, diversifiziertes und international tätiges Cannabisunternehmen, freut sich bekannt zu geben, dass das Unternehmen eine Gewerbeschutzrechts- und Abnahmevereinbarung über fünf Jahre mit ICC International Cannabis Corp. („ICC“) (CSE: WRLD.U) (Frankfurt: 8K51) (OTCPK: WLDCF) unterzeichnet hat. Gemäß dieser Vereinbarung wird AgraFlora in den nächsten fünf Jahren bis zu 100.000 kg getrocknete Cannabisblüten in Premium-Qualität, die im Gewächshauskomplex Delta gezüchtet wurden, an ICC verkaufen, vorausgesetzt, das Unternehmen erhält von Health Canada die entsprechenden Anbau- und Vertriebslizenzen. Es ist dies die zweite wichtige Liefervereinbarung, die mit AgraFlora ausgehandelt wurde. Die erste Vereinbarung mit einem Liefervolumen von jährlich bis zu 25.000 kg getrockneten Cannabisblüten in Premium-Qualität wurde mit Namaste Technologies Inc. abgeschlossen und am 13. Dezember 2018 bekannt gegeben.

  • Wissenschaftler glauben, dass ein Bestandteil von Cannabis eines Tages genutzt werden könnte, um Heroinabhängige zu behandeln – und damit die Opioidkrise in den USA zu bekämpfen.

  • TORONTO, ONTARIO. 21. Mai 2019 - Wayland Group Inc. (CSE: WAYL) (FRANKFURT: 75M) (OTCQB: MRRCF) ("Wayland" oder das "Unternehmen") gibt heute bekannt, dass der Joint Venture Partner DEMECAN GmbH ("DEMECAN"), an dem die Wayland Group 50% mit einer Option auf eine Erhöhung auf 60% hält, vom Bundesinstitut für Arzneimittel und Medizinprodukte ("BfArM") drei Lose zur inländischen Cannabisproduktion in Deutschland erhalten hat, nachdem die Beschwerde eines Teilnehmers nach einer mündlichen Verhandlung zurückgenommen wurde

  • Ein Sprecher des demokratischen Präsidentschaftskandidaten Joe Biden erklärte in der vergangenen Woche gegenüber dem TV-Sender CNN, dass dieser für die Entkriminalisierung von Marihuana eintrete. Unterstützung für eine vollständige Legalisierung wollte man aber nicht bestätigen.

  • Interessante Daten zum Markt für Medizinalcannabis veröffentlichte vor Kurzem New Frontier Data.

  • Auch wenn die Bewertungen einer Cannabisaktien aus dem Bereich Genussmittel teilweise bereits sehr hoch erscheinen, die positive Grundstimmung für den Sektor überwiegt bei Weitem.

  • Die Medizinalcannabisbranche hat in den letzten Monaten große Fortschritte gemacht. Neue Produkte, Innovationen und regulatorische Entscheidungen haben den Markt für Cannabinoid basierte Medikamente geöffnet. Auch Biotechunternehmen erkennen mittlerweile diese Chance und wollen sich einen Teil des Marktes für Cannabismedikamente sichern, berichtet Investing News Network.

  • EDMONTON, May 14, 2019 – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE:ACB) (TSX: ACB), announced today its financial and operational results for the third quarter ended March 31st, 2019.

    Third Quarter 2019 Highlights

    Unless otherwise stated, comparisons are made between Fiscal Q3 2019 and Fiscal Q2 2019 results)

    Continued solid revenue growth averaging 20% across all key markets, driven by successful scale up of the Company’s production and continued strong performance across the Canadian consumer, and Canadian and International medical cannabis markets:

    Canadian Consumer up 37%
    Canadian Medical up 8%
    International Medical up 40%

    Growth of the Company’s medical patient base, up by 5% to 77,136. As at the date of this release, Aurora has 82,745 active registered patients, a further increase of 7%, and continues to register new patients as product availability ramps up.

    Cash cost to produce per gram declined 26% to $1.42 per gram, as the initial impact of Aurora Sky’s scale and efficiency began to be realized.

    Production volume increased 99% to 15,590 kgs, up 1,200% year-over-year. The increase in production accelerated through the quarter, with the majority of the harvested volume realized in the last half of the quarter.

    SG&A expenses have stabilized with a modest increase of 1%, reflecting Aurora’s ongoing commitment to disciplined cost management.

    Average selling price per gram decreased marginally due to product mix effects (higher contribution from wholesale consumer), extraction capacity constraints resulting in extract-based products comprising 18% of net cannabis sales, and the first full quarter impact of excise tax on medical cannabis.

    Adjusted EBITDA loss improved by 20% to $36.6 million as the company continues to track towards achieving EBITDA positive results beginning in Q4 2019 as operations continue to ramp up.

    In January 2019, Aurora completed a US$345 million Convertible Notes offering, with the proceeds earmarked to continue the Company’s pace of growth in Canada and internationally. IFRS accounting standards require a mark-to-market adjustment at each period end for the derivative portion of these notes. Due to the increase in Aurora’s stock price since the issuance of the notes, the Company recorded a $102 million non-cash fair value loss in the Q3 2019 profit and loss statement.

    Management Commentary

    I’m exceptionally proud of our company and team as Aurora continues to deliver on our domestic and international growth strategy. We achieved solid revenue growth and strong operating results in a quarter proven challenging across the industry. We are laser focused on building a long-term sustainable business.

    During the quarter, we formally welcomed Nelson Peltz a key strategic advisor. He has been incredibly engaged, collaborative, and strategically focused on assisting our pursuit of growth in global markets and with mature companies in adjacent industries.

    Glen Ibbott, CFO, added, “Aurora is an extremely active and diversified company, leading the industry in cannabis research, product development, cultivation, global scale, and revenue growth. With a solid Q3 on all fronts, it’s time to move the yardsticks for the industry again. The company we have built with purpose through both organic growth and targeted acquisitions has provided a unique opportunity: continue to lead the industry in revenue growth while also progressing to positive operating earnings in the near term.”

    Outlook

    The Aurora Sky and Bradford facilities are now operating at full capacity. With this, the Company’s annualized production run rate across its operational facilities is in excess of 150,000 kg per annum, based on planted rooms.

    Aurora reiterates its target for Q4 with production available for sale in excess of 25,000 kg. Management intends to allocate a portion of this capacity to its inventory for manufacturing new products. Aurora remains focused on having vapes and certain edibles ready for launch under new regulations in the Canadian consumer market which are expected toward the end of the calendar year.

    With production ramping up, the Company continues to scale up manufacturing capacity, with innovation and technologies aimed at reducing time from harvest to market. The Company anticipates that increased processing, packaging and delivery efficiencies in Q4 and beyond will accelerate availability of product.

    Supply to Europe and other international markets is expected to increase as more of Aurora’s production facilities receive EU GMP certification. The Bradford facility has recently undergone an audit to obtain EU GMP certification. In Q3, the Company began exports of full spectrum cannabis extracts in Germany. Management anticipates these sales will contribute to growth given the higher margins in extracts.

    Oil extraction capacity has been a constraint during the second and third fiscal quarters of 2019. Subsequent to quarter’s end, Aurora expanded its internal extraction capacity to almost 7,000 kgs per quarter currently and will reach almost 16,000 kgs per quarter in fiscal Q1. As well, the Company’s extraction partner Radient Technologies is scaling up commercial production at its Edmonton facility. Consequently, Aurora anticipates production of extract-based products to increase, with the full impact starting to materialize towards the end of fiscal Q4. This increase in internal and external extraction capacity will enhance Aurora’s ability to produce derivative products at scale, which management expects will have a positive impact on both revenues and gross margin.

    With Aurora Sky now operating at full capacity, the Company anticipates continued reduction in production and manufacturing costs allowing cash costs per gram to continue to trend lower. Management reiterates its expectation that the average cash cost to produce per gram at its Sky Class facilities will be below $1.

    With disciplined cost management, the Company expects SG&A costs to grow modestly over the remainder of the fiscal year. Consequently, management anticipates that with sustained revenue growth and lower cash costs per gram, Aurora is well positioned to achieve positive EBITDA beginning in fiscal Q4 2019 (calendar Q2 2019).

    Q3 2019 Facility and Production Update

    Aurora defines production rate as the capacity of all planted rooms that have been approved by the regulator for sales, using anticipated annualized harvests at maturity based on a historical yield per plant. These targeted yields have been met or exceeded at all of Aurora’s current operating facilities.

    Construction at Aurora Sky is complete, and all grow rooms have been licensed by Health Canada. Fully planted, Aurora Sky is operating at its full design capacity of over 100,000 kg per annum.
    All rooms at Bradford are licensed by Health Canada and the facility has been fully planted. The facility has received no major observations during its audit to obtain EU GMP certification. Obtaining this certificate will substantially increase the Company’s capacity to ship product to the European market.
    The first saleable harvest at Aurora Nordic 1 is expected by the end of fiscal Q4 2019, with product sales anticipated in December 2019, or as soon as regulatory approvals are provided. Initial harvests for testing and licensing purposes have been completed successfully.
    Construction of Aurora Sun is progressing well, with the facility anticipated to be ready for planting by mid calendar 2020. Aurora Sun will measure 1.62 million square feet, reflecting a 33% increase from its originally planned size.
    Erection of the steel structure is well underway and anticipated for completion in late June 2019.
    Construction of the glass roof has commenced and is anticipated for completion shortly after installation of the steel structure.
    Whistler Alpha Lake is currently operating at its designed capacity of 480 kg/year of organic certified cannabis, utilizing four grow rooms.
    Construction of Whistler Pemberton remains on track for completion in calendar Q4 2019
    Four rooms are fully operational with an annual capacity of 1,200kg of organic certified cannabis
    11 additional rooms are expected to come online beginning in November 2019
    Upon completion Pemberton is expected to produce 4,500 kg/year of organic certified cannabis
    The Pemberton facility will incorporate a public lounge to educate visitors about WMMC and its history as cultivation pioneers of organic certified cannabis
    During the most recent grow season in Europe, Agropro harvested a combined 3,950 acres of hemp across Lithuania, Latvia and Estonia. For the upcoming grow season, beginning in May 2019, Agropro plans to contract 8,150 acres of hemp for harvest, which is expected to begin in August.
    Q3 2019 and Subsequent Corporate Highlights

    Acquisitions

    Acquisition of Whistler Medical Marijuana Corporation (“Whistler”)
    On March 1, 2019, Aurora acquired Whistler, an iconic Canadian organic cannabis brand which commands a significant premium for its products in both the Canadian medical and consumer markets. The Company is currently scaling up Whistler’s operations and anticipates an increase in products available for sale for the remainder of the calendar year.

    Acquisition of Hempco Food and Fiber Inc. (“Hempco”)
    On April 16, 2019, the Company entered a binding letter agreement with Hempco to acquire all of the issued and outstanding shares of Hempco. The acquisition will strengthen the Company’s industrial hemp and CBD-from-hemp infrastructure.

    Acquisition of Chemi Pharmaceuticals Inc. (“Chemi”)
    On April 24, 2019, the Company acquired Chemi, an Ontario-based laboratory specializing in high quality analytics services for the pharmaceutical and cannabis industries. The acquisition is intended to expand the Company’s analytical services for derivative products.

    Strategic Developments

    Appointment of Nelson Peltz
    On March 13, 2019, the Company appointed Nelson Peltz as a strategic advisor to work collaboratively with Aurora on exploring global expansion and partnership opportunities. Management believes the Company is well positioned to pursue partnerships across a number of industry verticals and is working with Mr. Peltz and his team to assess opportunities.

    Aurora Polaris
    On February 12, 2019, the Company announced the construction of Aurora Polaris, a 300,000 square foot international logistics hub and facility for the industrial-scale production of derivative cannabis products. Construction is on schedule and the Company anticipates completion towards the end of the calendar year. In anticipation of new regulations, the Company is in the process of installing interim production lines in licensed space across its production infrastructure in Canada to ensure a full complement of products will be available for sale in substantial quantities when permitted.

    International Expansion

    German Cannabis Production Tender
    On April 5, 2019, the Company was selected by the German Federal Institute for Drugs and Medical Devices as one of three winners in a public tender to cultivate and distribute medical cannabis in Germany. Aurora scored highest across 11 of 13 tender lots and was allotted the maximum number given to any LP of five. Aurora has commenced work on the construction of a facility in Germany and anticipated product to reach the German market in October 2020. Management expects that becoming a local producer will strengthen brand awareness and market development in a large and important market.

    Exports of Medical Cannabis to the United Kingdom
    On February 11, 2019, the Company completed its first commercial export of cannabis oil to the United Kingdom. Under the new UK framework, specialist doctors can legally issue prescriptions for cannabis-based medicines when they agree that their patients could benefit from this treatment.

    Expansion into Portugal
    On February 26, 2019, the Company created Aurora Portugal Lda. through an agreement to acquire a 51% ownership interest in Gaia Pharm Lda. Construction of an EU GMP compliant production cannabis facility is now underway in Portugal.
    Exports of Cannabis Oil to Germany
    On March 11, 2019, the Company commenced sales of cannabis oils to German pharmacies. Aurora’s full spectrum extract is differentiated in a market predominantly serviced with synthetic cannabinoids. With this, management believes the Company has a significant competitive advantage to establish early mover leadership, brand awareness and sales growth in this higher margin segment.

    Financing Activities

    Offering of Convertible Notes
    On January 24, 2019, the Company closed an offering of Convertible Notes for gross proceeds of US$345 million to fuel Canadian and international expansion initiatives, for future acquisitions and for general corporate purposes, including working capital requirements to continue the Company’s accelerated growth.

    Filing of Final Base Shelf Prospectus and Prospectus Supplement for At-the-Market Offering
    On May 10, 2019, the Company filed a final short-form base shelf prospectus (the “Shelf Prospectus”) with the securities commissions in each of the provinces of Canada, except Quebec, and a corresponding shelf registration statement with the United States Securities and Exchange Commission on Form F-10. These filings allow the Company to qualify the distribution under a prospectus in Canada and the United States of up to US$750,000,000 of common shares, warrants, subscription receipts, debt securities, or any combination of such securities (all of the foregoing, collectively, the “Shelf Securities”) during the 25-month period that the final short form base shelf prospectus remains effective. The specific terms of any future offerings under the Shelf Prospectus will be established in a prospectus supplement. Any prospectus supplement will be filed with the applicable securities regulatory authorities in connection with such offering.

    Filing of Final Base Shelf Prospectus and Prospectus Supplement for At-the-Market Offering
    On May 10, 2019, the Company filed a final short-form base shelf prospectus (the “Shelf Prospectus”) with the securities commissions in each of the provinces of Canada, except Quebec, and a corresponding shelf registration statement with the United States Securities and Exchange Commission on Form F-10. These filings allow the Company to qualify the distribution under a prospectus in Canada and the United States of up to US$750,000,000 of common shares, warrants, subscription receipts, debt securities, or any combination of such securities (all of the foregoing, collectively, the “Shelf Securities”) during the 25-month period that the final short form base shelf prospectus remains effective. The specific terms of any future offerings under the Shelf Prospectus will be established in a prospectus supplement. Any prospectus supplement will be filed with the applicable securities regulatory authorities in connection with such offering.

    On May 14, 2019, the Company filed a prospectus supplement (the “Prospectus Supplement”) to the Shelf Prospectus.In connection with the Prospectus Supplement, Aurora entered into a Sales Agreement dated May 14, 2019 with Cowen and Company, LLC (“Cowen”) and BMO Capital Markets (“BMO”) who will act as the selling agents (the “Selling Agents”) for the sale of common shares of Aurora (the “Common Shares”) by way of “at-the-market distributions” on the New York Stock Exchange in the United States. Subject to the terms of the Sales Agreement and applicable regulatory requirements, Common Shares in the aggregate amount of up to US$400,000,000 may be issued and sold from time to time at the discretion of Aurora over a period of up to 25 months. The Common Shares will be distributed at market prices prevailing at the time of the sale of such Common Shares and, as a result, prices may vary as between purchasers and during the period of distribution. The net proceeds of such sales, if any, will be used for general corporate purposes, including: (i) working capital; (ii) potential future acquisitions; (iii) debt repayments; and (iv) capital expenditures. The volume and timing of sales, if any, of Common Shares is at the discretion of Aurora.

    Aurora expects to use the net proceeds from the prospectus will support its expansion initiatives, global partnership strategy, and to continue the Company’s accelerated growth.

    The Shelf Prospectus and Prospectus Supplement have been filed on SEDAR and the U.S. version of the Shelf Prospectus and the Prospectus Supplement have been filed on the SEC’s website (www.sec.gov).

    This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

    Options Grant

    The Company granted a total of 383,000 options to purchase common shares of Aurora to Directors and Officers of the Company. The options vest annually over 36 months and have a weighted average exercise price of $9.35 per common share.

    Conference Call

    Aurora will host a conference call tomorrow, May 15, 2019, to discuss these results. Terry Booth, Chief Executive Officer, Glen Ibbott, Chief Financial Officer, Cam Battley, Chief Corporate Officer, and Michael Singer, Executive Chairman, will host the call starting at 10:30 a.m. Eastern time. A question and answer session will follow management’s presentation.

    Date: Wednesday, May 15th, 2019
    Time: 10:30 a.m. Eastern Time | 8:30 a.m. Mountain Time
    Webcast: https://bit.ly/2GRpDP3
    Replay: (416) 849-0833 or (855) 859-2056 until 12:00 midnight Eastern Time Wednesday, May 22, 2019
    Reference Number: 1103129

    ¹Non-IFRS measures are defined in the company’s MD&A.

    About Aurora

    Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 24 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

    Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora’s facilities is built to meet EU GMP standards. EU GMP certification has been granted to Aurora’s first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland.

    In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 16 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, and Chemi Pharmaceutical – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI) and EnWave Corporate (TSXV: ENW).

    Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index.

    For more information about Aurora, please visit our investor website, investor.auroramj.com

  • Laut einem Bericht der New York Post prüfen die Einzelhandelsriesen Walmart (NYSE WMT / WKN 860853) und Target (NYSE TGT / WKN 856243) die Möglichkeit, CBD-Produkte (Cannabidiol) anzubieten.

  • Medienberichten zufolge plant der mexikanische Präsident Andrés Manuel López Obrador eine 180 Gradwende im Krieg gegen Drogen. Er schlage ein Ende der Prohibition für alle derzeit illegalen Substanzen vor, hieß es.

  • TORONTO, May 13, 2019 /PRNewswire/ - The Green Organic Dutchman Holdings Ltd. (TGOD) (TSX: TGOD) (US: TGODF) is pleased to announce that its wholly owned subsidiary, HemPoland, has entered into an agreement with Mediakos UG haftungsbeschraenkt (Mediakos) to be the exclusive distributor of CannabiGold, its premium hemp CBD brand, for the German pharmacy market.

  • TORONTO, May 13, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America, reports that the Company's previously announced agreement for the acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which at closing will own all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"), is progressing as planned and the Company is in the latter stages of securing local regulatory approvals in Uruguay for the completion of the Acquisition. The Company has received conditional approval for the Acquisition from the TSX Venture Exchange Inc. ("TSXV").

  • Im Englischen gibt es die Redewendung: „Put your money where your mouth is“, was übersetzt soviel heißt, wie „Investiere selbst da, wofür du andere zu gewinnen suchst“. In diesem Sinne hat jetzt der CEO von Next GreenWave (CSE: NGW) ein deutliches Zeichen gesetzt.

  • Chemistree Technology Inc. (CNSX: CHM / FRA: CM1) trotzt dem Abwärtstrend, der den Cannabismarkt in den vergangenen Wochen erfasst hat und behauptet seinen Aufwärtstrend mit relativer Stärke.

  • Das ist ein Paukenschlag! Nabis Holdings (CSE: NAB / FRA: 71P) – noch unter Innovative Properties firmierend – gibt die nächste Übernahme viel versprechender Cannabis-Assets bekannt – diesmal in Washington State. Das Unternehmen verleibt sich nicht nur eine Extraktions- und Produktionsequipment sowie das Recht zum Leasing einer Produktionsanlage von PDT Technologies in Townsend an, sondern auch die exklusiven Lizenzrechte an einer der führenden und bekanntesten Cannabis-Marken für Washington State!

Wir setzen Cookies zum Betrieb und zur Sicherheit der Seite ein, aber auch Dienste Dritter setzen Cookies zum Webtracking bzw. Marketing.
Hinweise zum Datenschutz, Dienste Dritter und Widerspruch finden Sie in unserer Datenschutzerklärung